JNJ
$125.85
Johnson & Johnson
($.09)
(.07%)
Earnings Details
2nd Quarter June 2018
Tuesday, July 17, 2018 6:40:00 AM
Tweet Share Watch
Summary

Johnson & Johnson Reports In-line

Johnson & Johnson (JNJ) reported 2nd Quarter June 2018 earnings of $2.10 per share on revenue of $20.8 billion. The consensus earnings estimate was $2.06 per share on revenue of $20.3 billion. The Earnings Whisper number was $2.10 per share. Revenue grew 10.6% on a year-over-year basis.

The company said it expects 2018 earnings of $8.07 to $8.17 per share on revenue of $80.50 billion to $81.30 billion. The company's previous guidance was earnings of $8.00 to $8.20 per share on revenue of $81.00 billion to $81.80 billion and the current consensus earnings estimate is $8.13 per share on revenue of $81.56 billion for the year ending December 31, 2018.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.

Results
Reported Earnings
$2.10
Earnings Whisper
$2.10
Consensus Estimate
$2.06
Reported Revenue
$20.83 Bil
Revenue Estimate
$20.25 Bil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Johnson & Johnson Reports 2018 Second-Quarter Results:

NEW BRUNSWICK, N.J., July 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $20.8 billion for the second quarter of 2018, an increase of 10.6% as compared to the second quarter of 2017. Operational sales results increased 8.7% and the positive impact of currency was 1.9%. Domestic sales increased 9.4%. International sales increased 11.8%, reflecting operational growth of 7.9% and a positive currency impact of 3.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.3%, domestic sales increased 5.7% and international sales increased 6.8%.*

Net earnings and diluted earnings per share for the second quarter of 2018 were $4.0 billion and $1.45, respectively. Second-quarter 2018 net earnings included after-tax intangible amortization expense of approximately $1.0 billion and a charge for after-tax special items of approximately $0.8 billion. Second-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.4 billion and a charge for after-tax special items of approximately $0.8 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.7 billion and adjusted diluted earnings per share were $2.10, representing increases of 14.0% and 14.8%, respectively, as compared to the same period in 2017.* On an operational basis, adjusted diluted earnings per share also increased 11.5%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Our strong second-quarter results reflect double-digit growth in our Pharmaceutical business and the accelerating sales momentum in our Medical Devices business, driven by the continued growth of our market leading products and strategic new launches. We remain focused on investing in innovation and meeting the needs of our customers by delivering innovative products and solutions that position the company to deliver long-term, sustainable growth," said Alex Gorsky, Chairman and Chief Executive Officer. "Our talented J&J colleagues are united in our efforts to address some of the most critical health and consumer needs of people around the world."

The Company updated its sales guidance for the full-year 2018 to a range of $80.5 to $81.3 billion. This reflects an increase in expected operational growth to a range of 4.5% to 5.5%, partially offset by the estimated lower favorable impact of currency. Additionally, the Company updated its adjusted earnings guidance for full-year 2018 to a range of $8.07 to $8.17 per share. This reflects an increase in expected operational growth to a range of 8.5% to 9.9%, partially offset by the estimated lower favorable impact of currency.

Segment Sales Performance
Worldwide Consumer sales of $3.5 billion for the second quarter 2018 represented an increase of 0.7% versus the prior year, consisting of an operational decrease of 0.4% and a positive impact from currency of 1.1%. Domestic sales decreased 0.7%, international sales increased 1.9%, which reflected no change in operational sales and a positive currency impact of 1.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.9%, domestic sales decreased 0.7% and international sales increased 2.1%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products including TYLENOL analgesics and digestive health products, international beauty products primarily NEUTROGENA, OGX and Dr. Ci Labo, partially offset by lower sales of baby care products. During the quarter, the divestiture of the anti-dandruff shampoo brand NIZORAL and certain other ketoconazole-based shampoo brands was completed.

Worldwide Pharmaceutical sales of $10.4 billion for the second quarter 2018 represented an increase of 19.9% versus the prior year with an operational increase of 17.6% and a positive impact from currency of 2.3%. Domestic sales increased 17.7%; international sales increased 22.9%, which reflected an operational increase of 17.5% and a positive currency impact of 5.4%. Sales included the impact of Actelion Ltd which contributed 6.6%, to worldwide operational sales growth. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 11.0%, domestic sales increased 10.2% and international sales increased 11.9%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, DARZALEX (daratumumab), for the treatment of patients with multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis. SIMPONI/SIMPONI ARIA (golimumab), a biologic for the treatment of a number of immune- mediated inflammatory diseases, INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, and XARELTO (rivaroxaban), an oral anticoagulant.

During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for DARZALEX (daratumumab) in combination with VELCADE (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. The European Commission granted marketing authorization for JULUCA (dolutegravir/rilpivirine), a two-drug regimen, once-daily, single-pill for the treatment of HIV-1. A supplemental New Drug Application was submitted to the FDA seeking to expand the indication of OPSUMIT (macitentan) to include the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) to improve exercise capacity and pulmonary vascular resistance.

Also in the quarter, the acquisition of BeneVir Biopharm, Inc., a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies, was completed. In addition, a worldwide collaboration was entered into with Bristol-Myers Squibb Company to develop and commercialize Factor XIa inhibitors, including BMS-986177, for the prevention and treatment of major thrombotic conditions.

Worldwide Medical Devices sales of $7.0 billion for the second quarter 2018 represented an increase of 3.7% versus the prior year consisting of an operational increase of 1.9% and a positive currency impact of 1.8%. Domestic sales increased 1.1%; international sales increased 6.0%, which reflected an operational increase of 2.5% and a positive currency impact of 3.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.9%, domestic sales increased 1.7% and international sales increased 4.1%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by ACUVUE contact lenses and surgical products in the Vision business; electrophysiology products in the Interventional Solutions business; biosurgicals and international endocutters in the Advanced Surgery business; wound closure products in the General Surgery business and trauma products in the Orthopaedics business, partially offset by declines in the Diabetes Care business and spine products in the Orthopaedics business.

During the quarter, the Company announced acceptance of the binding offer from Platinum Equity to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. The Company also announced receipt of a binding offer from Fortive Corporation to acquire its Advanced Sterilization Products business for an aggregate value of approximately $2.8 billion, subject to customary adjustments. In addition, the FDA approved iDESIGN Refractive Studio, part of a next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction.

In July, the acquisition of assets from Medical Enterprises Distribution, LLC, a privately held developer of surgical impactor technology, including the automated ME1000 Surgical Impactor for use in hip replacement, was completed.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at  www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at  www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found on the company's website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward- looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws, global health care reforms and import/export and trade laws; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2018


2017


Total


Operations


Currency


2018


2017


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$   1,476


1,487


(0.7)

%

(0.7)


-


$   2,912


2,901


0.4

%

0.4


-

    International

2,028


1,991


1.9


0.0


1.9


3,990


3,805


4.9


0.5


4.4


3,504


3,478


0.7


(0.4)


1.1


6,902


6,706


2.9


0.4


2.5





















Pharmaceutical




















    U.S.

5,899


5,010


17.7


17.7


-


11,253


9,882


13.9


13.9


-

    International

4,455


3,625


22.9


17.5


5.4


8,945


6,998


27.8


19.9


7.9


10,354


8,635


19.9


17.6


2.3


20,198


16,880


19.7


16.4


3.3





















Medical Devices




















    U.S.

3,265


3,229


1.1


1.1


-


6,426


6,321


1.7


1.7


-

    International

3,707


3,497


6.0


2.5


3.5


7,313


6,698


9.2


3.3


5.9


6,972


6,726


3.7


1.9


1.8


13,739


13,019


5.5


2.5


3.0





















U.S.

10,640


9,726


9.4


9.4


-


20,591


19,104


7.8


7.8


-

International

10,190


9,113


11.8


7.9


3.9


20,248


17,501


15.7


9.3


6.4

Worldwide

$ 20,830


18,839


10.6

%

8.7


1.9


$ 40,839


36,605


11.6

%

8.6


3.0





















 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2018


2017


Total


Operations


Currency


2018


2017


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$ 10,640


9,726


9.4

%

9.4


-


$ 20,591


19,104


7.8

%

7.8


-





















Europe

4,810


4,232


13.7


6.5


7.2


9,607


8,090


18.8


8.2


10.6

Western Hemisphere excluding U.S.

1,540


1,499


2.7


6.7


(4.0)


3,107


2,953


5.2


6.9


(1.7)

Asia-Pacific, Africa

3,840


3,382


13.5


10.2


3.3


7,534


6,458


16.7


11.9


4.8

International

10,190


9,113


11.8


7.9


3.9


20,248


17,501


15.7


9.3


6.4





















Worldwide

$ 20,830


18,839


10.6

%

8.7


1.9


$ 40,839


36,605


11.6

%

8.6


3.0

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2018



2017*


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$    20,830


100.0


$    18,839


100.0


10.6

Cost of products sold

6,927


33.3


5,846


31.0


18.5

Gross Profit

13,903


66.7


12,993


69.0


7.0

Selling, marketing and administrative expenses

5,743


27.5


5,289


28.1


8.6

Research and development expense

2,639


12.7


2,296


12.2


14.9

Interest (income) expense, net

127


0.6


122


0.6



Other (income) expense, net

364


1.7


527


2.8



Restructuring

57


0.3


11


0.1



Earnings before provision for taxes on income

4,973


23.9


4,748


25.2


4.7

Provision for taxes on income

1,019


4.9


921


4.9


10.6

Net earnings

$      3,954


19.0


$      3,827


20.3


3.3











Net earnings per share (Diluted)

$        1.45




$        1.40




3.6











Average shares outstanding (Diluted)

2,721.3




2,741.5















Effective tax rate

20.5

%



19.4

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$      7,014


33.7


$      6,285


33.4


11.6

Net earnings

$      5,718


27.5


$      5,017


26.6


14.0

Net earnings per share (Diluted)

$        2.10




$        1.83




14.8

Effective tax rate

18.5

%



20.2

%














(1)See Reconciliation of Non-GAAP Financial Measures.










*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2018


2017*


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$    40,839


100.0


$    36,605


100.0


11.6

Cost of products sold

13,541


33.2


11,255


30.8


20.3

Gross Profit

27,298


66.8


25,350


69.2


7.7

Selling, marketing and administrative expenses

11,006


27.0


10,052


27.5


9.5

Research and development expense

5,043


12.3


4,366


11.9


15.5

Interest (income) expense, net

272


0.7


205


0.6



Other (income) expense, net

424


1.0


308


0.8



Restructuring

99


0.2


96


0.2



Earnings before provision for taxes on income

10,454


25.6


10,323


28.2


1.3

Provision for taxes on income

2,133


5.2


2,074


5.7


2.8

Net earnings

$      8,321


20.4


$      8,249


22.5


0.9











Net earnings per share (Diluted)

$        3.05




$        3.00




1.7











Average shares outstanding (Diluted)

2,728.5




2,749.4















Effective tax rate

20.4

%



20.1

%














Adjusted earnings before provision for taxes and net earnings (1)










Earnings before provision for taxes on income

$    13,872


34.0


$    12,388


33.8


12.0

Net earnings

$    11,353


27.8


$    10,055


27.5


12.9

Net earnings per share (Diluted)

$        4.16




$        3.66




13.7

Effective tax rate

18.2

%



18.8

%














(1)See Reconciliation of Non-GAAP Financial Measures.










*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07

 

Johnson & Johnson and Subsidiaries















Reconciliation of Non-GAAP Financial Measures
































Second Quarter


% Incr. /



Six Months YTD


% Incr. /


(Dollars in Millions Except Per Share Data)


2018


2017


(Decr.)



2018


2017


(Decr.)

















Earnings before provision for taxes on income - as reported


$      4,973


4,748


4.7

%


$    10,454


10,323


1.3

%

Intangible asset amortization expense


1,084


480





2,199


809




Litigation expense, net


703


493





703


493




Restructuring/Other (1)


176


128





283


289




Actelion acquisition related cost


64


213





160


213




Diabetes asset impairment


4


182





4


182




AMO acquisition related cost


25


41





46


79




Unrealized loss/(gain) on securities


(39)


-





(12)


-




Other


24


-





35


-




Earnings before provision for taxes on income - as adjusted


$      7,014


6,285


11.6

%


$    13,872


12,388


12.0

%
















Net Earnings - as reported


$      3,954


3,827


3.3

%


$      8,321


8,249


0.9

%

Intangible asset amortization expense


967


378





1,963


622




Litigation expense, net


609


352





609


352




Restructuring/Other


152


101





233


222




Actelion acquisition related cost


64


199





156


199




Diabetes asset impairment


3


125





3


125




AMO acquisition related cost


22


35





39


286




Unrealized loss/(gain) on securities


(31)


-





(10)


-




Impact of tax legislation (2)


(40)


-





12


-




Other


18


-





27


-




Net Earnings - as adjusted 


$      5,718


5,017


14.0

%


$    11,353


10,055


12.9

%
















Diluted Net Earnings per share - as reported


$        1.45


1.40


3.6

%


$        3.05


3.00


1.7

%

Intangible asset amortization expense


0.36


0.14





0.72


0.23




Litigation expense, net


0.22


0.13





0.22


0.13




Restructuring/Other


0.06


0.03





0.09


0.08




Actelion acquisition related cost


0.02


0.07





0.05


0.07




Diabetes asset impairment


-


0.05





-


0.05




AMO acquisition related cost


0.01


0.01





0.01


0.10




Unrealized loss/(gain) on securities


(0.01)


-





-


-




Impact of tax legislation


(0.02)


-





0.01


-




Other


0.01


-





0.01


-




Diluted Net Earnings per share - as adjusted 


$        2.10


1.83


14.8

%


$        4.16


3.66


13.7

%
















Operational Diluted Net Earnings per share - as adjusted 















at 2016 foreign currency exchange rates




1.86







3.72



















Impact of currency at 2017 foreign currency exchange rates


(0.06)


(0.03)





(0.19)


(0.06)



















Operational Diluted Net Earnings per share - as adjusted 















at 2017 foreign currency exchange rates


$        2.04


1.83


11.5

%


$        3.97


3.66


8.5

%
















(1)Includes $44M recorded in cost of products sold and $75M recorded in other (income) expense for the second quarter 2018. Includes $50M recorded in cost of products sold


and $134M recorded in other (income) expense for six months 2018 YTD.  Includes $13M recorded in cost of products sold and $104M recorded in other (income) expense for the 


second quarter 2017.  Includes $17M recorded in cost of products sold and $176M recorded in other (income) expense for six months 2017 YTD.





















(2)Includes foreign currency translation















 

 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions and Divestitures

 SECOND QUARTER 2018 ACTUAL vs. 2017 ACTUAL 










 Segments 



 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational %(1)

 WW As Reported: 


(0.4)%


17.6%


1.9%


8.7%

 U.S. 


(0.7)%


17.7%


1.1%


9.4%

 International 


0.0%


17.5%


2.5%


7.9%










Pulmonary Hypertension









Actelion




(6.3)




(3.0)

 U.S. 




(7.4)




(3.8)

 International 




(5.2)




(2.0)










Cardiovascular / Metabolism / Other









Actelion




(0.3)




(0.1)

 U.S. 




(0.1)




(0.1)

 International 




(0.4)




(0.2)










Spine & Other 









Codman Neuroscience






1.0


0.4

 U.S. 






0.6


0.2

 International 






1.5


0.6










Wound Care / Other


1.0






0.2

Compeed


0.0






0.0

 U.S. 


1.7






0.4

 International 


















All Other Acquisitions and Divestitures


0.3




0.0


0.1

 U.S. 


0.0




0.0


0.0

 International 


0.4




0.1


0.1










WW Ops excluding Acquisitions and Divestitures


0.9%


11.0%


2.9%


6.3%

 U.S. 


(0.7)%


10.2%


1.7%


5.7%

 International 


2.1%


11.9%


4.1%


6.8%










(1)Operational growth excludes the effect of translational currency









 

Johnson & Johnson and Subsidiaries









Reconciliation of Non-GAAP Financial Measure


















Operational Sales Growth Excluding Acquisitions and Divestitures

 SIX MONTHS 2018 ACTUAL vs. 2017 ACTUAL 










 Segments 



 Consumer 


 Pharmaceutical 


 Medical Devices 


 Total 



Operational %(1)

 WW As Reported: 


0.4%


16.4%


2.5%


8.6%

 U.S. 


0.4%


13.9%


1.7%


7.8%

 International 


0.5%


19.9%


3.3%


9.3%










Pulmonary Hypertension









Actelion




(6.8)




(3.1)

 U.S. 




(7.4)




(3.8)

 International 




(5.9)




(2.4)










Cardiovascular / Metabolism / Other









Actelion




(0.3)




(0.2)

 U.S. 




(0.2)




(0.1)

 International 




(0.5)




(0.2)










Spine & Other 









Codman Neuroscience






1.0


0.3

 U.S. 






0.6


0.2

 International 






1.4


0.6










Wound Care / Other









Compeed


0.9






0.2

 U.S. 


0.0






0.0

 International 


1.5






0.4










Vision









   Vision Surgical & Eye Health Business






(1.5)


(0.5)

  U.S.  






(1.4)


(0.5)

  International  






(1.6)


(0.6)










All Other Acquisitions and Divestitures


0.1




0.0


0.0

 U.S. 


0.0




(0.2)


0.0

 International 


0.3




0.1


0.1










WW Ops excluding Acquisitions and Divestitures


1.4%


9.3%


2.0%


5.3%

 U.S. 


0.4%


6.3%


0.7%


3.6%

 International 


2.3%


13.5%


3.2%


7.2%










(1)Operational growth excludes the effect of translational currency









 

 



REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2018


2017

Reported

Operational (1)

Currency



2018


2017

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) 
















BABY CARE
















US


$        89


$    113

-21.2%

-21.2%

-



$      186


$      226

-17.7%

-17.7%

-

Intl


367


381

-3.7%

-2.7%

-1.0%



727


723

0.6%

-0.8%

1.4%

WW


456


494

-7.7%

-6.9%

-0.8%



913


949

-3.8%

-4.8%

1.0%

BEAUTY
















US


637


649

-1.8%

-1.8%

-



1,248


1,216

2.6%

2.6%

-

Intl


472


427

10.5%

7.3%

3.2%



945


841

12.4%

6.8%

5.6%

WW


1,109


1,076

3.1%

1.8%

1.3%



2,193


2,057

6.6%

4.3%

2.3%

ORAL CARE
















US


157


150

4.7%

4.7%

-



314


306

2.6%

2.6%

-

Intl


236


244

-3.3%

-5.5%

2.2%



458


450

1.8%

-2.7%

4.5%

WW


393


394

-0.3%

-1.7%

1.4%



772


756

2.1%

-0.6%

2.7%

OTC
















US


454


432

5.1%

5.1%

-



919


909

1.1%

1.1%

-

Intl


612


574

6.6%

2.5%

4.1%



1,219


1,110

9.8%

3.2%

6.6%

WW


1,066


1,006

6.0%

3.7%

2.3%



2,138


2,019

5.9%

2.2%

3.7%

WOMEN'S HEALTH
















US


4


3

33.3%

33.3%

-



7


6

16.7%

16.7%

-

Intl


276


273

1.1%

1.9%

-0.8%



516


512

0.8%

-1.1%

1.9%

WW


280


276

1.4%

2.2%

-0.8%



523


518

1.0%

-0.9%

1.9%

WOUND CARE / OTHER
















US


135


140

-3.6%

-3.6%

-



238


238

0.0%

0.0%

-

Intl


65


92

-29.3%

-31.3%

2.0%



125


169

-26.0%

-29.2%

3.2%

WW


200


232

-13.8%

-14.6%

0.8%



363


407

-10.8%

-12.1%

1.3%

















TOTAL CONSUMER
















US


1,476


1,487

-0.7%

-0.7%

-



2,912


2,901

0.4%

0.4%

-

Intl


2,028


1,991

1.9%

0.0%

1.9%



3,990


3,805

4.9%

0.5%

4.4%

WW


$   3,504


$ 3,478

0.7%

-0.4%

1.1%



$   6,902


$   6,706

2.9%

0.4%

2.5%

































See footnotes at end of schedule





















REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2018


2017

Reported

Operational (1)

Currency



2018


2017

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2)(5)
















IMMUNOLOGY
















US


$   2,317


$ 2,101

10.3%

10.3%

-



$   4,317


$   4,224

2.2%

2.2%

-

Intl


1,021


858

19.0%

14.6%

4.4%



2,063


1,665

23.9%

17.0%

6.9%

WW


3,338


2,959

12.8%

11.5%

1.3%



6,380


5,889

8.3%

6.3%

2.0%

REMICADE
















US 


918


1,064

-13.7%

-13.7%

-



1,834


2,246

-18.3%

-18.3%

-

US Exports (3)


104


127

-18.1%

-18.1%

-



246


292

-15.8%

-15.8%

-

Intl


298


339

-12.1%

-14.0%

1.9%



629


664

-5.3%

-9.0%

3.7%

WW


1,320


1,530

-13.7%

-14.1%

0.4%



2,709


3,202

-15.4%

-16.2%

0.8%

SIMPONI / SIMPONI ARIA
















US


274


230

19.1%

19.1%

-



498


459

8.5%

8.5%

-

Intl


274


209

31.1%

26.9%

4.2%



568


408

39.2%

32.0%

7.2%

WW


548


439

24.8%

22.8%

2.0%



1,066


867

23.0%

19.6%

3.4%

STELARA
















US


919


680

35.1%

35.1%

-



1,571


1,227

28.0%

28.0%

-

Intl


422


303

39.3%

32.0%

7.3%



831


579

43.5%

32.9%

10.6%

WW


1,341


983

36.4%

34.2%

2.2%



2,402


1,806

33.0%

29.6%

3.4%

OTHER IMMUNOLOGY
















US


102


-

*

*

-



168


-

*

*

-

Intl


27


7

*

*

*



35


14

*

*

*

WW


129


7

*

*

*



203


14

*

*

*

INFECTIOUS DISEASES
















US


328


341

-3.8%

-3.8%

-



661


667

-0.9%

-0.9%

-

Intl


521


451

15.5%

11.0%

4.5%



1,018


874

16.5%

8.5%

8.0%

WW


849


792

7.2%

4.6%

2.6%



1,679


1,541

9.0%

4.5%

4.5%

EDURANT / rilpivirine
















US


15


17

-11.8%

-11.8%

-



29


29

0.0%

0.0%

-

Intl


196


162

21.0%

13.1%

7.9%



392


299

31.1%

18.6%

12.5%

WW


211


179

17.9%

10.7%

7.2%



421


328

28.4%

17.0%

11.4%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
















US


277


278

-0.4%

-0.4%

-



550


537

2.4%

2.4%

-

Intl


215


176

22.2%

18.8%

3.4%



420


347

21.0%

14.1%

6.9%

WW


492


454

8.4%

7.1%

1.3%



970


884

9.7%

7.0%

2.7%

OTHER INFECTIOUS DISEASES
















US


36


46

-21.7%

-21.7%

-



82


101

-18.8%

-18.8%

-

Intl


110


113

-2.7%

-4.1%

1.4%



206


228

-9.6%

-13.3%

3.7%

WW


146


159

-8.2%

-9.2%

1.0%



288


329

-12.5%

-15.1%

2.6%









REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2018


2017

Reported

Operational (1)

Currency



2018


2017

Reported

Operational (1)

Currency

NEUROSCIENCE
















US


639


620

3.1%

3.1%

-



1,263


1,284

-1.6%

-1.6%

-

Intl


889


847

5.0%

1.4%

3.6%



1,824


1,680

8.6%

2.4%

6.2%

WW


1,528


1,467

4.2%

2.1%

2.1%



3,087


2,964

4.1%

0.6%

3.5%

CONCERTA / methlyphenidate
















US


68


76

-10.5%

-10.5%

-



134


184

-27.2%

-27.2%

-

Intl


115


105

9.5%

6.9%

2.6%



222


206

7.8%

3.1%

4.7%

WW


183


181

1.1%

-0.4%

1.5%



356


390

-8.7%

-11.2%

2.5%

INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA
















US


438


387

13.2%

13.2%

-



838


759

10.4%

10.4%

-

Intl


282


242

16.5%

10.5%

6.0%



578


474

21.9%

12.8%

9.1%

WW


720


629

14.5%

12.2%

2.3%



1,416


1,233

14.8%

11.3%

3.5%

RISPERDAL CONSTA
















US


80


91

-12.1%

-12.1%

-



162


186

-12.9%

-12.9%

-

Intl


108


116

-6.9%

-10.3%

3.4%



222


228

-2.6%

-8.7%

6.1%

WW


188


207

-9.2%

-11.1%

1.9%



384


414

-7.2%

-10.6%

3.4%

OTHER NEUROSCIENCE
















US


53


66

-19.7%

-19.7%

-



129


155

-16.8%

-16.8%

-

Intl


384


384

0.0%

-2.4%

2.4%



802


772

3.9%

-1.0%

4.9%

WW


437


450

-2.9%

-5.0%

2.1%



931


927

0.4%

-3.6%

4.0%

ONCOLOGY
















US


1,085


697

55.7%

55.7%

-



2,018


1,361

48.3%

48.3%

-

Intl


1,371


1,030

33.1%

27.2%

5.9%



2,749


1,960

40.3%

30.7%

9.6%

WW


2,456


1,727

42.2%

38.7%

3.5%



4,767


3,321

43.5%

37.8%

5.7%

DARZALEX
















US


298


212

40.6%

40.6%

-



562


413

36.1%

36.1%

-

Intl


213


87

*

*

*



381


141

*

*

*

WW


511


299

70.9%

67.7%

3.2%



943


554

70.2%

65.8%

4.4%

IMBRUVICA
















US


250


202

23.8%

23.8%

-



477


392

21.7%

21.7%

-

Intl


370


248

49.2%

42.7%

6.5%



730


467

56.3%

45.7%

10.6%

WW


620


450

37.8%

34.2%

3.6%



1,207


859

40.5%

34.7%

5.8%

VELCADE
















US


-


-

-

-

-



-


-

-

-

-

Intl


280


290

-3.4%

-8.0%

4.6%



593


570

4.0%

-3.4%

7.4%

WW


280


290

-3.4%

-8.0%

4.6%



593


570

4.0%

-3.4%

7.4%

ZYTIGA
















US


486


241

*

*

-



893


474

88.4%

88.4%

-

Intl


423


317

33.4%

27.3%

6.1%



861


607

41.8%

31.8%

10.0%

WW


909


558

62.9%

59.5%

3.4%



1,754


1,081

62.3%

56.7%

5.6%

OTHER ONCOLOGY
















US


51


42

21.4%

21.4%

-



86


82

4.9%

4.9%

-

Intl


85


88

-3.4%

-6.8%

3.4%



184


175

5.1%

-1.5%

6.6%

WW


136


130

4.6%

2.3%

2.3%



270


257

5.1%

0.6%

4.5%


























REPORTED SALES vs. PRIOR PERIOD ($MM)




SECOND QUARTER


SIX MONTHS








% Change






% Change





2018


2017

Reported

Operational (1)

Currency



2018


2017

Reported

Operational (1)

Currency



PULMONARY HYPERTENSION(4)


















US


429


37

*

*

-



790


37

*

*

-



Intl


236


48

*

*

 * 



460


48

*

*

 * 



WW


665


85

*

*

 * 



1,250


85

*

*

 * 



OPSUMIT


















US


180


24

*

*

-



329


24

*

*

-



Intl


131


21

*

*

 * 



253


21

*

*

 * 



WW


311


45

*

*

 * 



582


45

*

*

 * 



TRACLEER


















US


71


2

*

*

-



139


2

*

*

-



Intl


72


24

*

*

 * 



144


24

*

*

 * 



WW


143


26

*

*

 * 



283


26

*

*

 * 



UPTRAVI


















US


155


8

*

*

-



279


8

*

*

-



Intl


16


1

*

*

 * 



32


1

*

*

 * 



WW


171


9

*

*

 * 



311


9

*

*

 * 



OTHER


















US


23


3

*

*

-



43


3

*

*

-



Intl


17


2

*

*

 * 



31


2

*

*

 * 



WW


40


5

*

*

 * 



74


5

*

*

 * 



CARDIOVASCULAR / METABOLISM / OTHER


















US


1,101


1,214

-9.3%

-9.3%

-



2,204


2,309

-4.5%

-4.5%

-



Intl


417


391

6.6%

1.9%

4.7%



831


771

7.8%

1.7%

6.1%



WW


1,518


1,605

-5.4%

-6.6%

1.2%



3,035


3,080

-1.5%

-3.0%

1.5%



XARELTO


















US


679


642

5.8%

5.8%

-



1,257


1,155

8.8%

8.8%

-



Intl


-


-

-

-

-



-


-

-

-

-



WW


679


642

5.8%

5.8%

-



1,257


1,155

8.8%

8.8%

-



INVOKANA / INVOKAMET


















US


169


256

-34.0%

-34.0%

-



373


503

-25.8%

-25.8%

-



Intl


46


39

17.9%

13.0%

4.9%



90


76

18.4%

11.7%

6.7%



WW


215


295

-27.1%

-27.7%

0.6%



463


579

-20.0%

-20.9%

0.9%



PROCRIT / EPREX


















US


156


174

-10.3%

-10.3%

-



345


343

0.6%

0.6%

-



Intl


80


81

-1.2%

-5.9%

4.7%



167


159

5.0%

-1.7%

6.7%



WW


236


255

-7.5%

-9.0%

1.5%



512


502

2.0%

-0.1%

2.1%



OTHER


















US


97


142

-31.7%

-31.7%

-



229


308

-25.6%

-25.6%

-



Intl


291


271

7.4%

2.7%

4.7%



574


536

7.1%

1.3%

5.8%



WW


388


413

-6.1%

-9.2%

3.1%



803


844

-4.9%

-8.6%

3.7%



TOTAL PHARMACEUTICAL


















US


5,899


5,010

17.7%

17.7%

-



11,253


9,882

13.9%

13.9%

-



Intl


4,455


3,625

22.9%

17.5%

5.4%



8,945


6,998

27.8%

19.9%

7.9%



WW


$ 10,354


$ 8,635

19.9%

17.6%

2.3%



$ 20,198


$ 16,880

19.7%

16.4%

3.3%
















See footnotes at end of schedule















REPORTED SALES vs. PRIOR PERIOD ($MM)




SECOND QUARTER


SIX MONTHS








% Change






% Change





2018


2017

Reported

Operational (1)

Currency



2018


2017

Reported

Operational (1)

Currency



MEDICAL DEVICES SEGMENT (2)(5)


















DIABETES CARE


















US


$      129


$    160

-19.4%

-19.4%

-



$      246


$      314

-21.7%

-21.7%

-



Intl


226


261

-13.4%

-16.3%

2.9%



448


506

-11.5%

-16.6%

5.1%



WW


355


421

-15.7%

-17.5%

1.8%



694


820

-15.4%

-18.5%

3.1%



DIAGNOSTICS


















US


-


-

-

-

-



-


-

-

-

-



Intl


-


-

-

-

-



-


1

*

*

*



WW


-


-

-

-

-



-


1

*

*

*



INTERVENTIONAL SOLUTIONS


















US


323


285

13.3%

13.3%

0.0%



627


564

11.2%

11.2%

-



Intl


344


288

19.4%

14.1%

5.3%



680


558

21.9%

14.2%

7.7%



WW


667


573

16.4%

13.7%

2.7%



1,307


1,122

16.5%

12.7%

3.8%



ORTHOPAEDICS


















US 


1,332


1,367

-2.6%

-2.6%

-



2,639


2,726

-3.2%

-3.2%

-



Intl


930


926

0.4%

-3.6%

4.0%



1,873


1,842

1.7%

-4.6%

6.3%



WW


2,262


2,293

-1.4%

-3.0%

1.6%



4,512


4,568

-1.2%

-3.8%

2.6%



HIPS


















US


211


208

1.4%

1.4%

-



420


417

0.7%

0.7%

-



Intl


149


142

4.9%

0.8%

4.1%



303


285

6.3%

-0.2%

6.5%



WW


360


350

2.9%

1.2%

1.7%



723


702

3.0%

0.3%

2.7%



KNEES


















US


229


236

-3.0%

-3.0%

-



457


482

-5.2%

-5.2%

-



Intl


153


149

2.7%

-0.8%

3.5%



312


301

3.7%

-2.5%

6.2%



WW


382


385

-0.8%

-2.2%

1.4%



769


783

-1.8%

-4.2%

2.4%



TRAUMA


















US


394


390

1.0%

1.0%

-



801


781

2.6%

2.6%

-



Intl


281


253

11.1%

6.7%

4.4%



570


504

13.1%

6.2%

6.9%



WW


675


643

5.0%

3.3%

1.7%



1,371


1,285

6.7%

4.0%

2.7%



SPINE & OTHER


















US


498


533

-6.6%

-6.6%

-



961


1,046

-8.1%

-8.1%

-



Intl


347


382

-9.2%

-13.2%

4.0%



688


752

-8.5%

-14.5%

6.0%



WW


845


915

-7.7%

-9.4%

1.7%



1,649


1,798

-8.3%

-10.8%

2.5%



SURGERY


















US


1,022


1,012

1.0%

1.0%

-



2,015


2,007

0.4%

0.4%

-



Intl


1,493


1,372

8.8%

5.4%

3.4%



2,923


2,648

10.4%

4.7%

5.7%



WW


2,515


2,384

5.5%

3.5%

2.0%



4,938


4,655

6.1%

2.9%

3.2%



ADVANCED


















US


402


400

0.5%

0.5%

-



795


792

0.4%

0.4%

-



Intl


603


533

13.1%

9.1%

4.0%



1,176


1,018

15.5%

9.3%

6.2%



WW


1,005


933

7.7%

5.4%

2.3%



1,971


1,810

8.9%

5.4%

3.5%



GENERAL


















US


436


423

3.1%

3.1%

-



859


846

1.5%

1.5%

-



Intl


733


691

6.1%

2.9%

3.2%



1,437


1,342

7.1%

1.5%

5.6%



WW


1,169


1,114

4.9%

2.9%

2.0%



2,296


2,188

4.9%

1.5%

3.4%



SPECIALTY


















US


184


189

-2.6%

-2.6%

-



361


369

-2.2%

-2.2%

-



Intl


157


148

6.1%

4.2%

1.9%



310


288

7.6%

3.4%

4.2%



WW


341


337

1.2%

0.4%

0.8%



671


657

2.1%

0.3%

1.8%



VISION


















US


459


405

13.3%

13.3%

-



899


710

26.6%

26.6%

-



Intl


714


650

9.8%

7.2%

2.6%



1,389


1,143

21.5%

16.3%

5.2%



WW


1,173


1,055

11.2%

9.6%

1.6%



2,288


1,853

23.5%

20.3%

3.2%



CONTACT LENSES / OTHER


















US


320


274

16.8%

16.8%

-



629


530

18.7%

18.7%

-



Intl


524


479

9.4%

6.8%

2.6%



1,022


906

12.8%

8.0%

4.8%



WW


844


753

12.1%

10.4%

1.7%



1,651


1,436

15.0%

12.0%

3.0%



SURGICAL


















US


139


131

6.1%

6.1%

-



270


180

50.0%

50.0%

-



Intl


190


171

11.1%

8.6%

2.5%



367


237

54.9%

48.3%

6.6%



WW


329


302

8.9%

7.5%

1.4%



637


417

52.8%

49.1%

3.7%





















TOTAL MEDICAL DEVICES


















US


3,265


3,229

1.1%

1.1%

-



6,426


6,321

1.7%

1.7%

-



Intl


3,707


3,497

6.0%

2.5%

3.5%



7,313


6,698

9.2%

3.3%

5.9%



WW


$   6,972


6,726

3.7%

1.9%

1.8%



$ 13,739


$ 13,019

5.5%

2.5%

3.0%







































* Percentage greater than 100% or not meaningful


















(1) Operational growth excludes the effect of translational currency
















(2) Unaudited


















(3) Reported as U.S. sales


















(4) Products acquired from Actelion acquisition on June 16, 2017
















(5) Prior year amounts have been reclassified to conform to current year product disclosure 













     

(PRNewsfoto/Johnson & Johnson)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2018-second-quarter-results-300682014.html

SOURCE Johnson & Johnson